Patient P-03260

Synthetic patientONX-7 · Day 149 · 75+ · M · baseline S19Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Unstable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

56%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S19
Day 99 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 99.

Primary contributors, last 14 days

Inflammatory activity-9
Nutritional resilience+7
GI instability-3
Treatment adherence+2

What helped?

No interventions yet.

LIFE OS recommendation

GI Support Protocol GI-04

67%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 53
Autonomic recovery ↑65
- WearableResting HR 77 bpm
- Wearable1,876 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 50

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Intermediate metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.6 · butyrate capacity 40/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 53 ms
Sleep: 6.4 h
Steps: 2,743
Resting HR: 77 bpm

Daily log: GI score 60, nutritional resilience 40, adherence 67.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03357	48%	S02	CR-01	improved	50
P-03191	45%	S19	GI-04	improved	51
P-03225	42%	S19	GI-04	improved	50
P-03465	42%	S17	CR-01	improved	65
P-03166	41%	S20	CR-01	improved	62
P-03201	39%	S15	GI-04	improved	68
P-03323	39%	S14	GI-04	improved	48
P-03146	38%	S14	GI-04	improved	53
P-03382	38%	S01	GI-04	improved	56
P-03099	37%	S17	CR-01	improved	55
P-03123	37%	S14	GI-04	improved	50
P-03070	36%	S14	GI-04	improved	51